About Us
Business Strategy
Silence is executing a two-pronged strategy to best leverage its drug development expertise and broad RNAi therapeutic platform toward the creation of corporate and shareholder value.
This strategy is based on:
- Leveraging broad, proprietary RNAi technology base to establish multiple additional partnerships with global pharmaceutical and biotechnology companies across a diverse range of therapeutic opportunities
- Continuing development of partnered and internal RNAi therapeutic pipeline
